CCND1 and cancer: The NFκB pathway is regarded as an emerging cancer drug target because NFκB transcription factors are crucial regulators associated with numerous hallmarks of cancer, including inflammatory (IL6, CXCL1, CXCL5, CXCL8, and MCP1), proliferation (MYC, CCND1, CCNE2, and CDK2), metastatic (MMP2/9), and angiogenic (VEGF)37.